

1 **Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-**
2 **breakthrough infections: a multi-center cohort study**

3 Po Ying Chia, MBBS^{1,2,4}; Sean Wei Xiang Ong, MBBS^{1,2}; Calvin J Chiew, MPH^{1,3}; Li Wei Ang, MSc¹; Jean-
4 Marc Chavatte PhD¹; Tze-Minn Mak, PhD¹; Lin Cui, PhD¹; Shirin Kalimuddin, MPH^{5,6}; Wan Ni Chia,
5 PhD⁶; Chee Wah Tan, PhD⁶; Louis Yi Ann Chai, PhD^{7,8}; Seow Yen Tan, MBBS⁹; Shuwei Zheng, MBBS¹⁰;
6 Raymond Tzer Pin Lin, MBBS¹; Linfa Wang, PhD⁶; Yee-Sin Leo, MPH^{1,2,4,8}; Vernon J Lee, PhD³; David
7 Chien Lye, MBBS^{1,2,4,8}; Barnaby Edward Young, MB BChir^{1,2,4}

8

9 ¹ National Centre for Infectious Diseases, Singapore

10 ² Tan Tock Seng Hospital, Singapore

11 ³ Ministry of Health, Singapore

12 ⁴ Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

13 ⁵ Singapore General Hospital, Singapore

14 ⁶ Duke-NUS Medical School, National University of Singapore, Singapore

15 ⁷ National University Health System, Singapore

16 ⁸ Yong Loo Lin School of Medicine, National University of Singapore, Singapore

17 ⁹ Changi General Hospital, Singapore

18 ¹⁰ Sengkang General Hospital, Singapore

19

20 **Running title:** Delta VOC: Viral Kinetics for Vaccinated

21 **Corresponding Author:**

22 Barnaby Young, National Centre for Infectious Diseases, 16 Jln Tan Tock Seng, Singapore 308442

23 E-mail: Barnaby_young@ncid.sg; Telephone: (+65) 6256 6011

24 **Keywords:** COVID-19; SARS-CoV-2; breakthrough infection; delta; variants of concern; vaccine

25 breakthrough; vaccination

26 **Objectives**

27 Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
28 been developed but variants of concerns (VOCs) with mutations in the spike protein are worrisome,
29 especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination
30 alters virological and serological kinetics in breakthrough infections.

31 **Methods**

32 We conducted a multi-centre retrospective cohort study of patients in Singapore who had received a
33 licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We
34 compared the clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and
35 surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals.

36 **Results**

37 Of 218 individuals with B.1.617.2 infection, 84 had received a mRNA vaccine of which 71 were fully
38 vaccinated, 130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in
39 the vaccine breakthrough group, the odds of severe COVID-19 requiring oxygen supplementation
40 was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, $p=0.001$).
41 PCR cycle threshold (Ct) values were similar between both vaccinated and unvaccinated groups at
42 diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-
43 spike protein antibodies was observed in vaccinated patients, however, these titers were
44 significantly lower against B.1.617.2 as compared with the wildtype vaccine strain.

45 **Conclusion**

46 The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated
47 with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust
48 serological response. Vaccination remains a key strategy for control of COVID-19 pandemic.

49

50 **Background**

51 Availability of effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
52 2) within one year of the first report of coronavirus disease 2019 (COVID-19) is remarkable. Phase 3
53 clinical trials of messenger RNA (mRNA) vaccines have demonstrated 92-95% efficacy in preventing
54 symptomatic infection and severe disease [1-4] and intensive vaccination programs have reduced
55 infection and mortality rates in multiple settings [5-7].

56 Emerging variants of concern (VOCs), such as B.1.1.7 (Alpha in the World Health Organization
57 classification), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta) exhibit varied sequence changes
58 and alteration of amino acid sequences of the spike protein. This has led to concerns of viral immune
59 evasion and decreased vaccine effectiveness. Furthermore, these VOCs have been shown to be more
60 transmissible [8-10], and B.1.1.7 and B.1.617.2 has been associated with increased disease severity
61 and hospitalization [11, 12]. B.1.617.2 has rapidly spread outside India, becoming the most
62 frequently sequenced lineage worldwide by end of June 2021 [13]. Case series of vaccine-
63 breakthrough infections have reported an over-representation by these VOCs [14, 15].

64 Understanding vaccine effectiveness in the context of VOCs requires granular data: which vaccines
65 were administered, at what time point prior to infection, number of doses, and particularly which
66 VOC has caused the infection. Important VOC-specific vaccination outcomes include severity of
67 infection and vaccine effects on transmission.

68 The COVID-19 vaccination program was initiated in Singapore on 30 December 2020, with free
69 vaccinations provided to all Singapore residents in phases, beginning with the elderly and those in
70 high-risk occupations such as healthcare workers. Vaccines used are mRNA vaccines,
71 Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273. As of 19 July 2021, 6,837,200 vaccine doses
72 had been administered and ~2,792,430 individuals (47% of the total population) had completed the
73 vaccination course [16]. In May 2021, B.1.617.2 became the dominant circulating variant based on
74 local sequencing data.

75 In this multi-center cohort study, we characterize the clinical features, virological and serological
76 kinetics of patients with vaccine-breakthrough PCR-confirmed B.1.617.2 infection and compared
77 them with unvaccinated patients.

78 **Methods**

79 **Patient Recruitment**

80 Adults aged ≥ 18 years with COVID-19 confirmed by positive SARS-CoV-2 PCR and admitted to any of
81 the five study sites from 1 April to 14 June 2021 were screened. Patients with B.1.617.2 infection
82 (identification methods delineated below) were included in this analysis. Vaccine-breakthrough
83 infection was defined as PCR-confirmed COVID-19 with symptom onset or first positive PCR
84 (whichever was earlier) ≥ 14 days following a second dose of BNT162b2 or mRNA-1273 vaccine.
85 Incomplete vaccination was defined as receipt of one dose of these vaccines ≥ 14 days prior to
86 symptom onset or first positive PCR. Patients who received non-mRNA vaccines or developed
87 infection within 14 days after the first dose were excluded from this analysis. B.1.617.2 vaccine-
88 breakthrough infections were compared with a retrospective cohort of unvaccinated patients with
89 B.1.617.2 infection admitted to one study site.

90 **Data Collection**

91 Clinical and laboratory data were collected from electronic medical records using a standardized
92 data-collection form [17]. Laboratory data including cycle threshold (Ct) values from SARS-CoV-2 RT-
93 PCR assays and serological results from Elecsys® (Roche, Basel, Switzerland) Anti-SARS-CoV-2
94 chemiluminescent immunoassays [anti-nucleocapsid (anti-N) and anti-spike protein (anti-S)] and
95 surrogate virologic neutralization test (sVNT) cPass™ (Genscript, NJ, USA) were recorded. cPass™
96 detects total neutralizing antibodies targeting the viral spike protein receptor-binding domain [18].
97 These tests were performed as part of routine clinical care.

98 **Additional Serologic testing**

99 Serum samples from a subset of vaccine-breakthrough patients who had separately consented for
100 specimen collection were additionally tested with a newly developed multiplex-sVNT assay using the
101 Luminex platform. Further details can be found in the supplementary information.

102 **Viral RNA sequencing and VOC determination**

103 SARS-CoV-2 PCR was performed using various commercially available assays in different clinical
104 laboratories. As part of active genomic surveillance, whole genome sequencing (WGS) by National
105 Public Health Laboratory is performed for all patients in Singapore with SARS-CoV-2 detected by RT-
106 PCR with a Ct value less than 30. Pangolin COVID-19 Lineage Assigner and CoVsurver were used to
107 assign lineage to each sequence. For individuals with PCR confirmed infection without available
108 sequencing results, lineage was inferred based on epidemiological investigations by the Singapore
109 Ministry of Health (MOH), and likely B.1.617.2 infections were included (i.e., clear epidemiologic link
110 with patients with sequencing confirmed B.1.617.2 infection).

111 **Clinical Management**

112 All individuals with confirmed COVID-19 (including asymptomatic cases) in Singapore are admitted to
113 hospital for inpatient evaluation and isolation. Individuals with pneumonia requiring supplemental
114 oxygen are treated with intravenous remdesivir, while dexamethasone and other agents were
115 reserved for progressive infections per national guidelines [19]. Disease severity was stratified into
116 asymptomatic, mild (no pneumonia on chest radiography), moderate (presence of pneumonia on
117 chest radiography), severe (requiring supplemental oxygen), or critical (requiring intensive care unit
118 [ICU] admission or mechanical ventilation). Collection of clinical data was censored on discharge
119 from hospital.

120 **Statistical Analysis**

121 For descriptive analysis, data were presented as median (interquartile range (IQR)) for continuous
122 parameters and frequency (percentage) for categorical variables. Chi-square and Fisher's exact tests

123 were used to compared categorical variables, while for continuous variables, t-test was used for
124 normal data and Mann-Whitney U test for non-normal data. For asymptomatic patients, the day of
125 confirmatory COVID-19 diagnosis was denoted as day one of illness. For symptomatic patients, the
126 day of symptom onset or the day of confirmatory COVID-19 diagnosis, whichever earlier, was
127 denoted as day one of illness.

128 Previously reported risk factors for disease severity [20] were evaluated and included in a
129 multivariate logistic regression model [21]. For serial Ct values, we fitted a generalized additive
130 mixed model (GAMM) with a random intercept by patient. To investigate the effect of vaccination
131 status on rate of increase of Ct value, we included fixed factors of vaccination status and day of
132 illness with smoothing terms and interaction between these two fixed factors. We plotted Ct values
133 with marginal effect of day of illness by vaccination status and 95% confidence intervals (CI) from the
134 GAMM.

135 For analysis of cPass™ and anti-S titres we fitted a GAMM to serial titres with random intercept by
136 patient in addition to fixed factor of day of illness with smoothing terms, separately for vaccine-
137 breakthrough and unvaccinated patients infected with Delta variant. We plotted cPass™/anti-S titres
138 with marginal effect of day of illness and 95%CI from GAMM for each group of vaccine-breakthrough
139 and unvaccinated patients.

140 *P*-values less than 0.05 were considered statistically significant, and all tests were 2-tailed. Data
141 analyses were performed using Stata Release 15 (StataCorp, College Station, TX) and R version 3.6.2
142 (R Foundation for Statistical Computing, Vienna, Austria).

143 **Ethical approval**

144 Written informed consent was obtained from study participants of the multi-centre study approved
145 by National Healthcare Group Domain Specific Review Board (NHG-DSRB) (Study Reference

146 2012/00917). Informed consent for retrospective data collection at National Centre for Infectious
147 Diseases (NCID) was waived (NHG-DSRB reference number 2020/01122).

148 **Results**

149 218 B.1.617.2 infections were identified across the five study sites (Supplementary Figure S1). Of
150 these, 71 met the definition for vaccine-breakthrough. An additional 13 only received one dose \geq 14
151 days prior to disease onset or received both doses but within 14 days of disease onset, while four
152 had received a non-mRNA vaccine overseas. Majority of participants meeting study definition for
153 vaccine-breakthrough had received two doses of BNT162b2 (n=66, 93%).

154 **Clinical Features**

155 In line with Singapore's national vaccination strategy wherein older adults were prioritized for
156 vaccination, our vaccine-breakthrough cohort was of significantly older age; median age of 56 years
157 (IQR:39-64) versus 39.5 (IQR:30-58) ($p<0.001$) (Table 1). Other baseline demographics were similar.

158 Vaccine-breakthrough patients were significantly more likely to be asymptomatic (28.2% versus
159 9.2%, $p<0.001$); and if symptomatic, had fewer number of symptoms (Table 1). Unvaccinated
160 individuals had worse levels of known biomarkers associated with increased COVID-19 severity
161 including lymphocyte count, C-reactive protein [CRP], lactate dehydrogenase [LDH] and alanine
162 transferase [ALT]. Correspondingly, a higher proportion of the unvaccinated cohort had pneumonia,
163 required supplementary oxygen and ICU admission compared with the vaccinated cohort. A broader
164 analysis comparing unvaccinated versus those who had received at least one dose of vaccine (i.e.
165 both vaccine-breakthrough and incomplete vaccination) demonstrated similar findings
166 (Supplementary Table T1).

167 Multivariate logistic regression analysis for development of severe COVID-19 (defined by
168 supplementary oxygen requirement) demonstrated that vaccination was protective with an adjusted
169 odds ratio (aOR) of 0.073 (95% confidence interval [CI]):0.016-0.343 ($p=0.001$) (Table 2). Analysis

170 comparing unvaccinated versus those who had received at least one dose of vaccine demonstrated
171 similar findings (Supplementary Table T2). Multivariate logistic regression analysis for development
172 of moderately severe COVID-19 (defined by development of pneumonia) also demonstrated that
173 vaccination was protective with aOR of 0.069 (95%CI:0.027-0.180) ($p<0.001$) (Supplementary Table
174 T3).

175 **Virologic kinetics**

176 Serial Ct values of individuals were analyzed as a surrogate marker for the viral load. The initial
177 median initial Ct value did not differ between unvaccinated and fully vaccinated patients
178 (unvaccinated median Ct 18.8 (14.9-22.7), vaccinated 19.2 (15.2-22.2), $p=0.929$). However, fully
179 vaccinated patients had a faster rate of increase in Ct value over time compared with unvaccinated
180 individuals, suggesting faster viral load decline (coefficient estimates for interaction terms ranged
181 from 9.12 (standard error 3.75) to 12.06 (standard error 3.03); p -value <0.05 for each interaction
182 terms) (Figure 1).

183 **Serologic data**

184 69 fully vaccinated individuals and 45 unvaccinated had serologic data available on record. 66/66
185 (100%) of vaccinated individuals had detectable S antibodies in week 1 of illness, while 7/45 (16%) of
186 unvaccinated individuals did (Supplementary Figure S2). There was no difference in the proportion
187 of individuals who seroconverted with the anti-N assay in week 1 (vaccinated 7/68 (10%) vs
188 unvaccinated 11/107 (10%)) or week 2 (vaccinated 2/11 (18%), unvaccinated 4/20 (20%).

189 Analysis of sVNT with cPass indicated very high inhibition among vaccinated individuals in week 1 of
190 illness (median 98.3% (IQR:91.0-99.4%)) which increased to 99.6% (IQR 99.3-99.9%) in week 2
191 (Figure 2A, 2B). Among unvaccinated individuals, median inhibition was below the 20% threshold at
192 both week 1 and week 2. Among the 37 vaccinated individuals with a serum sample available for

193 testing by the multiplex sVNT assay, titres were significantly higher against wildtype virus compared
194 with B.1.617.2 and other VOCs (Figure 3). sVNT titres were lowest against B.1.617.2 and P.1 VOCs.

195 **Discussion**

196 In this study, we found that fully vaccinated patients had significantly lower odds of moderate or
197 severe outcomes following infection by the SARS-CoV-2 VOC B.1.617.2. Vaccination was associated
198 with lower peak measures of systemic inflammation, fewer symptoms, including more asymptomatic
199 infection, and better clinical outcomes. Notably, in contrast to existing studies that showed lower
200 viral load in vaccinated patients [22], initial viral load indicated by PCR Ct values was similar between
201 vaccinated and unvaccinated patients with B.1.617.2. However, vaccinated patients appeared to
202 clear viral load at a faster rate. Our serologic data suggest an early rapid rise in neutralizing and
203 binding antibodies indicated by C-Pass and Roche anti-S antibodies, which may be evidence of
204 memory immunity to COVID-19 vaccination on challenge with a breakthrough infection with
205 B.1.617.2.

206 As part of active case finding and surveillance in Singapore, all patients with fever or respiratory
207 symptoms, close contacts of confirmed cases, and newly arrived travelers are screened for COVID-19
208 using PCR. Additionally, high-risk individuals in frontline occupations or congregate settings are
209 tested as part of routine surveillance. All confirmed COVID-19 cases are reported to MOH and
210 admitted to a hospital for initial evaluation. As such, our hospitalized cohort uniquely captures the
211 entire spectrum of disease severity of COVID-19 infection and provides granular data even for mild
212 and asymptomatic vaccine-breakthrough infections, giving us the opportunity to analyze virologic
213 and serologic kinetics of these patients.

214 The finding of diminished severity with B.1.617.2 infection in vaccinated individuals is reassuring and
215 corroborates emerging data from the United Kingdom which have found that mRNA vaccination
216 remains protective against symptomatic and severe disease[12, 23]. An observational cohort study
217 conducted in Scotland suggested that ≥ 14 days after the second dose, BNT162b2 vaccine offered

218 92% vaccine effectiveness against presumptive non-B.1.617.2 infection and 79% protection against
219 presumptive B.1.617.2 [24]. Protection associated with the ChAdOx1 nCoV-19 vaccine was 73% and
220 60% respectively. Although vaccine-breakthrough infections are increasingly reported, with the
221 largest series to date in the United States reporting 10,262 breakthrough infections, a majority of
222 these were mild (27% asymptomatic, 10% hospitalization, 2% mortality)[25]. Vaccine-breakthrough
223 infections will continue to be observed, especially with genetic drift and selection pressures resulting
224 in emergence of newer VOCs; however, it is likely that there will be a shift toward milder disease
225 spectrum with more widespread implementation of vaccination programs.

226 To our knowledge, we provide the first data characterizing impact of vaccination on virologic kinetics
227 by the B.1.617.2 variant. While initial Ct values were similar; the effect of vaccination with a more
228 rapid decline in viral load (and hence shorter duration of viral shedding) has implications on
229 transmissibility and infection control policy. A shorter duration of infectivity may allow a shorter
230 duration of isolation for vaccinated individuals. Based on our data, it seems likely that vaccination
231 reduces secondary transmission, though this needs to be further studied in larger community
232 surveillance studies. Other studies found similar impact of vaccination on other variants. Pritchard
233 and colleagues found that vaccinated individuals had higher Ct values compared with unvaccinated
234 individuals in B.1.1.7 infections [7], while Levine-Tiefenbaum and colleagues similarly found a
235 reduction in viral loads after BNT162b2 vaccine, though no data was provided on variant type [26].

236 There are several limitations to our study. Firstly, we only compared vaccine-breakthrough infections
237 with unvaccinated COVID-19 patients. We did not study vaccinated individuals who had similar
238 exposure risk but did not develop COVID-19 infection. We thus could not evaluate vaccine efficacy
239 against asymptomatic infection. We also did not have detailed epidemiologic data to study the effect
240 of vaccination on preventing secondary transmission.

241 Secondly, we could only obtain serologic tests after infection since patients were recruited after
242 confirmation of infection. While active contact tracing and case finding in Singapore resulted in early

243 identification of most COVID-19 cases, the first available serologic result was at a median of 2 (IQR:1-
244 3) days of illness and antibody levels are likely to already have been boosted by natural infection. We
245 thus could not evaluate the underlying immunologic mechanisms behind vaccine-breakthrough
246 infection, e.g., diminished neutralizing antibody level or impaired cellular immunity. Further study
247 should compare similarly exposed vaccinated individuals who develop breakthrough infection with
248 those who do not, to elucidate the underlying drivers of susceptibility, which may enlighten us on
249 how to optimize protection (e.g., through enhanced/boosted dosing schedules).

250 Thirdly, PCR testing was not standardized in a centralized laboratory, and instead conducted at each
251 centre using different validated commercial assays. Ct values are only a surrogate measure of viral
252 load and shedding. We did not evaluate viability of shed virus via viral culture. In addition, we only
253 evaluated participants with mRNA vaccination, and thus our findings are restricted to mRNA
254 vaccines and not all COVID-19 vaccines.

255 **Conclusion**

256 mRNA vaccines against COVID-19 are protective against symptomatic infection and severe disease
257 by the B.1.617.2 variant. Vaccinated individuals had a more rapid decline in viral load, which has
258 implications on secondary transmission and public health policy. Rapid and widespread
259 implementation of vaccination programs remains a key strategy for control of COVID-19 pandemic.
260 Further studies should elucidate immunologic features driving vaccine-breakthrough infection to
261 improve vaccine-induced protection.

262 **Conflict of Interest Disclosures**

263 BEY reports personal fees from Roche and Sanofi, outside the submitted work. All other authors
264 declare no competing interests.

265 **Acknowledgments**

266 We thank all clinical and nursing staff who provided care for the patients and staff in the Infectious
267 Disease Research and Training Office of the National Centre for Infectious Diseases who assisted
268 with data collection. We will also like to thank Jeremy Cutter at the National Public Health and
269 Epidemiology Unit of National Centre for Infectious Diseases who assisted with data management on
270 Ct values.

271 **Funding**

272 This study was funded by grants from the Singapore National Medical Research Council (COVID19RF-
273 001, COVID19RF-008). The funders had no role in the design and conduct of the study; collection,
274 management, analysis and interpretation of the data; preparation, review or approval of the
275 manuscript; and decision to submit the manuscript for publication.

276

277

278

279

280

281

282

283

284

285

286

287

288

	Unvaccinated n = 130	Vaccinated n = 71	p-value
Median age (IQR), years	39.5 (30-58)	56 (39-64)	<0.001
Male (%)	67 (51.5)	27 (38)	0.067
Median Charlson Comorbidity Index (IQR)	0 (0-1)	0 (0-0)	0.125
Diabetes mellitus (%)	28 (21.5)	5 (7.0)	0.008
Hypertension (%)	28 (21.5)	14 (19.7)	0.762
Hyperlipidaemia (%)	32 (24.6)	18 (25.4)	0.908
Median Ct value on diagnosis (IQR)*	18.8 (14.9-22.7)	19.2 (15.2-22.2)	0.929
Asymptomatic	12 (9.2)	20 (28.2)	<0.001
Symptom onset after Diagnosis (%)	11 (9.3)	11 (21.6)	0.030
Median day of illness symptoms start (IQR)	2 (2-3)	3 (2-3)	0.715
Median Ct values for Symptom Onset After (IQR)	21.87 (18.8-31.2)	19.2 (16.6-21.5)	0.279
Median Sum of Symptoms Reported (IQR)	2 (1-3)	1 (0-2)	<0.001
Fever (%)	96 (73.9)	29 (40.9)	<0.001
Cough (%)	79 (60.8)	27 (38)	0.002
Shortness of Breath (%)	17 (13.1)	1 (1.4)	0.004
Runny Nose (%)	31 (23.9)	27 (38)	0.034
Sore Throat (%)	43 (33.1)	18 (25.4)	0.255
Diarrhoea (%)	8 (6.2)	0	0.052
Median highest Neutrophil (IQR) × 10 ⁹ /L	4.50 (3.07-5.92)	4.33 (3.52-5.43)	0.117
Median lowest Lymphocyte (IQR) × 10 ⁹ /L	0.95 (0.65-1.50)	1.36 (1.02-1.87)	<0.001
Median highest C-Reactive Protein (IQR), mg/L	24.7 (6.9-84.8)	12.6 (6.5-22.5)	<0.001
Median highest Lactate Dehydrogenase (IQR), U/L	486 (365-672)	373 (314-421)	0.062
Median highest Alanine Transferase (IQR), U/L	35	19	<0.001

	(18-74)	(13-34)	
Disease Outcome			
Pneumonia (%)	69 (53.1)	9 (21.7)	<0.001
Supplementary O2 required (%)	27 (20.8)	2 (2.8)	<0.001
ICU admission required (%)	7 (5.4)	0	0.053
Median days of ICU admission required (IQR)	4 (3-9)	-	-
Intubation (%)	2 (1.5)	0	0.541
Median days of Intubation (IQR)	7 (3-11)	-	-
COVID-19 specific treatment (%)	39 (30)	5 (7)	<0.001
Mortality	2 (1.54)	0	0.541

289

290 Table 1: Baseline characteristics and disease outcome between unvaccinated and completed mRNA

291 vaccination COVID-19 B.1.617.2 infected patients

292


	Univariable model		Multivariable model	
	Crude OR (95% CI)	p-value	Adjusted OR (95% CI)	p-value
Vaccinated	0.111 (0.025-0.480)	0.003	0.073 (0.016-0.343)	0.001
Age group				
<45 years old	1	-	1	-
45-64 years old	6.19 (1.90-20.2)	0.003	8.29 (2.29-30.0)	0.001
>64 years old	13 (3.90-42.9)	<0.001	13.5 (2.66-68.8)	0.002
Male	0.913 (0.414-2.01)	0.821	1.09 (0.418-2.85)	0.857
Diabetes	6.18 (2.59-14.7)	<0.001	2.24 (0.785-6.41)	0.132
Hypertension	4.8 (2.09-11.0)	<0.001	1.62 (0.509-5.18)	0.413
Presence of other comorbidities, if any	3.96 (1.66-9.44)	0.002	0.897 (0.262-3.07)	0.862

293

294 **Table 2:** Odds ratio of candidate risk factors for development of severe COVID-19 for completed
 295 mRNA vaccination COVID-19 B.1.617.2 infected patients. CI, confidence interval; OR, odds ratio

296

297



298

299 **Figure 1:** Scatterplot of Ct values and marginal effect of day of illness of COVID-19 B.1.617.2 infected
300 patients with 95% confidence intervals from generalized additive mixed model with interaction term
301 between vaccination status and day of illness

302


303

304


305

306

307



308



309

310 **Figure 2:** (A) Spaghetti plot of surrogate virus neutralisation (sVNT) inhibition % as measured by


311 cPass; (B) Scatterplot of sVNT inhibition % and marginal effect of day of illness by vaccine-

312 breakthrough and unvaccinated groups of COVID-19 B.1.617.2 infected patients with 95% confidence

313 intervals from generalized additive mixed models. For both plots, n=127; vaccine-breakthrough = 67,
314 unvaccinated = 60

315

316



317

318 **Figure 3:** Violin plots of of surrogate virus neutralisation (sVNT) inhibition % against wildtype SARS-
319 CoV-2 and the B.1.617.2 variant for 36 patients with vaccine-breakthrough infection (median day of
320 sample collection from infection onset 6 days (inter-quartile range (IQR) 3-7). Titres against the four
321 variants were significantly lower than against wildtype SARS-CoV-2 [median sVNT, B.1.1.7 98.5%
322 (IQR: 96.3-99.5); B.1.351 98.2% (IQR: 95.3-99.5); B.1.617.2 96.0% (IQR: 90.9-99.3); P.1 95.5% (IQR:
323 91.3-98.9); Wildtype 99.4% (IQR: 98.5-99.7), Kruskal-Wallis p-value = 0.00055, Post-hoc pairwise
324 comparison (Conover) Wildtype versus each variant p<0.05]

325 References

- 326 [1] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Perez Marc,
327 E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li, W.V. Kalina, D.
328 Cooper, R.W. Frenck, Jr., L.L. Hammitt, O. Tureci, H. Nell, A. Schaefer, S. Unal, D.B. Tresnan, S.
329 Mather, P.R. Dormitzer, U. Sahin, K.U. Jansen, W.C. Gruber, C.C.T. Group, Safety and Efficacy of the
330 BNT162b2 mRNA Covid-19 Vaccine, *N Engl J Med* 383(27) (2020) 2603-2615.
- 331 [2] N. Dagan, N. Barda, E. Kepten, O. Miron, S. Perchik, M.A. Katz, M.A. Hernan, M. Lipsitch, B. Reis,
332 R.D. Balicer, BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, *N Engl J*
333 *Med* 384(15) (2021) 1412-1423.
- 334 [3] Y. Angel, A. Spitzer, O. Henig, E. Saiag, E. Sprecher, H. Padova, R. Ben-Ami, Association Between
335 Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2
336 Infections Among Health Care Workers, *JAMA* (2021).
- 337 [4] L.R. Baden, H.M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S.A. Spector, N.
338 Roupael, C.B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K.
339 Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J.
340 Ledgerwood, B.S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M.
341 Ivarsson, J. Miller, T. Zaks, C.S. Group, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, *N*
342 *Engl J Med* 384(5) (2021) 403-416.
- 343 [5] E.J. Haas, F.J. Angulo, J.M. McLaughlin, E. Anis, S.R. Singer, F. Khan, N. Brooks, M. Smaja, G.
344 Mircus, K. Pan, J. Southern, D.L. Swerdlow, L. Jodar, Y. Levy, S. Alroy-Preis, Impact and effectiveness
345 of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and
346 deaths following a nationwide vaccination campaign in Israel: an observational study using national
347 surveillance data, *Lancet* 397(10287) (2021) 1819-1829.
- 348 [6] E. Vasileiou, C.R. Simpson, T. Shi, S. Kerr, U. Agrawal, A. Akbari, S. Bedston, J. Beggs, D. Bradley, A.
349 Chuter, S. de Lusignan, A.B. Docherty, D. Ford, F.R. Hobbs, M. Joy, S.V. Katikireddi, J. Marple, C.
350 McCowan, D. McGagh, J. McMenamin, E. Moore, J.L. Murray, J. Pan, L. Ritchie, S.A. Shah, S. Stock, F.
351 Torabi, R.S. Tsang, R. Wood, M. Woolhouse, C. Robertson, A. Sheikh, Interim findings from first-dose
352 mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national
353 prospective cohort study, *Lancet* 397(10285) (2021) 1646-1657.
- 354 [7] E. Pritchard, P.C. Matthews, N. Stoesser, D.W. Eyre, O. Gethings, K.D. Vihta, J. Jones, T. House, H.
355 VanSteenHouse, I. Bell, J.I. Bell, J.N. Newton, J. Farrar, I. Diamond, E. Rourke, R. Studley, D. Crook,
356 T.E.A. Peto, A.S. Walker, K.B. Pouwels, Impact of vaccination on new SARS-CoV-2 infections in the
357 United Kingdom, *Nat Med* (2021).
- 358 [8] N.G. Davies, S. Abbott, R.C. Barnard, C.I. Jarvis, A.J. Kucharski, J.D. Munday, C.A.B. Pearson, T.W.
359 Russell, D.C. Tully, A.D. Washburne, T. Wenseleers, A. Gimma, W. Waites, K.L.M. Wong, K. van
360 Zandvoort, J.D. Silverman, C.C.-W. Group, C.-G.U. Consortium, K. Diaz-Ordaz, R. Keogh, R.M. Eggo, S.
361 Funk, M. Jit, K.E. Atkins, W.J. Edmunds, Estimated transmissibility and impact of SARS-CoV-2 lineage
362 B.1.1.7 in England, *Science* (2021).
- 363 [9] H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S.
364 Pillay, E.J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T. Mohale, A.J.
365 Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G. Marais, N.Y. Hsiao,
366 S. Korsman, M.A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals, S. Abrahams, O. Laguda-
367 Akingba, A. Alisoltani-Dehkordi, A. Godzik, C.K. Wibmer, B.T. Sewell, J. Lourenco, L.C.J. Alcantara, S.L.
368 Kosakovsky Pond, S. Weaver, D. Martin, R.J. Lessells, J.N. Bhiman, C. Williamson, T. de Oliveira,
369 Detection of a SARS-CoV-2 variant of concern in South Africa, *Nature* 592(7854) (2021) 438-443.
- 370 [10] R. Pung, T.M. Mak, A.J. Kucharski, V.J. Lee, Serial intervals observed in SARS-CoV-2 B.1.617.2
371 variant cases, *medRxiv* (2021) 2021.06.04.21258205.
- 372 [11] N.G. Davies, C.I. Jarvis, C.C.-W. Group, W.J. Edmunds, N.P. Jewell, K. Diaz-Ordaz, R.H. Keogh,
373 Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7, *Nature* (2021).

- 374 [12] A. Sheikh, J. McMenamain, B. Taylor, C. Robertson, SARS-CoV-2 Delta VOC in Scotland:
375 demographics, risk of hospital admission, and vaccine effectiveness, *Lancet* 397(10293) (2021) 2461-
376 2462.
- 377 [13] Á. O'Toole, Hill, V., and Rambaut Group, PANGO lineages International Lineage Report B.1.617.2
378 Report <https://cov-lineages.org/global_report_B.1.617.2.html>, (accessed 8 July 2021.).
- 379 [14] T. Kustin, N. Harel, U. Finkel, S. Perchik, S. Harari, M. Tahor, I. Caspi, R. Levy, M. Leshchinsky, S.
380 Ken Dror, G. Bergerzon, H. Gadban, F. Gadban, E. Eliassian, O. Shimron, L. Saleh, H. Ben-Zvi, E. Keren
381 Taraday, D. Amichay, A. Ben-Dor, D. Sagas, M. Strauss, Y. Shemer Avni, A. Huppert, E. Kepten, R.D.
382 Balicer, D. Netzer, S. Ben-Shachar, A. Stern, Evidence for increased breakthrough rates of SARS-CoV-
383 2 variants of concern in BNT162b2-mRNA-vaccinated individuals, *Nat Med* (2021).
- 384 [15] A.E. McEwen, S. Cohen, C. Bryson-Cahn, C. Liu, S.A. Pergam, J. Lynch, A. Schippers, K. Strand, E.
385 Whimbey, N.S. Mani, A.J. Zelikoff, V.A. Makarewicz, E.R. Brown, S.A.M. Bakhash, N.R. Baker, J.
386 Castor, R.J. Livingston, M.L. Huang, K.R. Jerome, A.L. Greninger, P. Roychoudhury, Variants of
387 concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in
388 Washington State, *Clin Infect Dis* (2021).
- 389 [16] Updates on COVID-19 (Coronavirus Disease 2019) Local Situation.
390 <<https://www.moh.gov.sg/covid-19>>, 2021 (accessed June 10 2021.).
- 391 [17] COVID-19 therapies and vaccine landscape, *Nat Mater* 19(8) (2020) 809.
- 392 [18] C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.I. Chen, C. Tiu, Z. Hu, V.C. Chen, B.E. Young, W.R. Sia, Y.J.
393 Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, L.F. Wang, A SARS-CoV-2 surrogate virus neutralization
394 test based on antibody-mediated blockage of ACE2-spike protein-protein interaction, *Nat Biotechnol*
395 38(9) (2020) 1073-1078.
- 396 [19] Treatment Guidelines for COVID-19. <<https://www.ncid.sg/Health-Professionals/Diseases-and-Conditions/Pages/COVID-19.aspx>>, 2021 (accessed 1 June 2021.).
- 397 [20] J.J.Y. Zhang, K.S. Lee, L.W. Ang, Y.S. Leo, B.E. Young, Risk Factors for Severe Disease and Efficacy
398 of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-
399 Regression Analysis, *Clin Infect Dis* 71(16) (2020) 2199-2206.
- 400 [21] J. Coveney, FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression.
401 Statistical Software Components S456948, Boston College Department of Economics, revised 25 Apr
402 2021., (2008).
- 403 [22] M.G. Thompson, J.L. Burgess, A.L. Naleway, H. Tyner, S.K. Yoon, J. Meece, L.E.W. Olsho, A.J.
404 Caban-Martinez, A.L. Fowlkes, K. Lutrick, H.C. Groom, K. Dunnigan, M.J. Odean, K. Hegmann, E.
405 Stefanski, L.J. Edwards, N. Schaefer-Solle, L. Grant, K. Ellingson, J.L. Kuntz, T. Zunie, M.S. Thiese, L.
406 Ivacic, M.G. Wesley, J. Mayo Lamberte, X. Sun, M.E. Smith, A.L. Phillips, K.D. Groover, Y.M. Yoo, J.
407 Gerald, R.T. Brown, M.K. Herring, G. Joseph, S. Beitel, T.C. Morrill, J. Mak, P. Rivers, B.P. Poe, B.
408 Lynch, Y. Zhou, J. Zhang, A. Kelleher, Y. Li, M. Dickerson, E. Hanson, K. Guenther, S. Tong, A.
409 Bateman, E. Reisdorf, J. Barnes, E. Azziz-Baumgartner, D.R. Hunt, M.L. Arvay, P. Kutty, A.M. Fry, M.
410 Gaglani, Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines, *New*
411 *England Journal of Medicine* (2021).
- 412 [23] J.L. Bernal, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E. Tessier, N.
413 Groves, G. Dabrera, R. Myers, C. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, K. Brown, S.
414 Hopkins, M. Chand, M. Ramsay, Effectiveness of COVID-19 vaccines against the B.1.617.2 variant,
415 *medRxiv* (2021) 2021.05.22.21257658.
- 416 [24] A. Sheikh, J. McMenamain, B. Taylor, C. Robertson, SARS-CoV-2 Delta VOC in Scotland:
417 demographics, risk of hospital admission, and vaccine effectiveness, *The Lancet* 397(10293) (2021)
418 2461-2462.
- 419 [25] CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough
420 Infections Reported to CDC — United States, January 1–April 30, 2021. *MMWR Morb Mortal Wkly*
421 *Rep* 2021;70:792–793. .

423 [26] M. Levine-Tiefenbrun, I. Yelin, R. Katz, E. Herzel, Z. Golan, L. Schreiber, T. Wolf, V. Nadler, A.
424 Ben-Tov, J. Kuint, S. Gazit, T. Patalon, G. Chodick, R. Kishony, Initial report of decreased SARS-CoV-2
425 viral load after inoculation with the BNT162b2 vaccine, Nat Med 27(5) (2021) 790-792.

426